Zheng Guansong, Yan Zhaojie, Zou Junrong, Zou Xiaofeng, Chai Keqiang, Zhang Guoxi
First Clinical College, Gannan Medical University, Ganzhou, China.
Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Front Oncol. 2025 Feb 3;15:1520808. doi: 10.3389/fonc.2025.1520808. eCollection 2025.
Prostate cancer ranks as one of the most common types of cancer affecting men worldwide, and its progression is shaped by a diverse array of influencing factors. The AR signaling pathway plays a pivotal role in the pathogenesis of prostate cancer. While existing anti-androgen treatments show initial efficacy, they ultimately do not succeed in halting the advancement to CRPC. Recent studies have identified alterations in the Hippo-YAP signaling pathway within prostate cancer, highlighting intricate crosstalk with the AR signaling pathway. In this review, we examine the interactions and underlying mechanisms between AR and YAP, the key molecules in these two signaling pathways. AR regulates the stability and function of YAP by modulating its transcription, translation, and phosphorylation status, while YAP exerts both promotional and inhibitory regulatory effects on AR. Based on these findings, this paper investigates their significant roles in the onset, progression, and therapeutic resistance of prostate cancer, and discusses the clinical potential of YAP in prostate cancer treatment.
前列腺癌是全球影响男性的最常见癌症类型之一，其进展受多种影响因素的塑造。AR信号通路在前列腺癌的发病机制中起关键作用。虽然现有的抗雄激素治疗显示出初步疗效，但最终未能成功阻止向去势抵抗性前列腺癌（CRPC）的进展。最近的研究已经确定了前列腺癌中Hippo-YAP信号通路的改变，突出了与AR信号通路的复杂相互作用。在这篇综述中，我们研究了这两个信号通路中的关键分子AR和YAP之间的相互作用及潜在机制。AR通过调节YAP的转录、翻译和磷酸化状态来调节其稳定性和功能，而YAP对AR既有促进作用又有抑制调节作用。基于这些发现，本文研究了它们在前列腺癌的发生、进展和治疗抵抗中的重要作用，并讨论了YAP在前列腺癌治疗中的临床潜力。
